Vaccine最新文献

{"title":"Virtual reality for routine immunisations in needle phobic children with and without developmental disabilities: A pilot study.","authors":"Allya Makhijani, Narelle Jenkins, Jessica Kaufman, Monsurul Hoq, Sabine Priestley, Sonja Elia, Ian McKenzie, Andrew Davidson, Paul Leong, Teresa Lazzaro, Sarah McNab, Margie Danchin","doi":"10.1016/j.vaccine.2024.126481","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126481","url":null,"abstract":"<p><p>Virtual reality for routine immunisations in needle phobic children with and without developmental disabilities: a pilot study.</p><p><strong>Background: </strong>Virtual Reality (VR) headsets can improve needle procedure success and experiences for children, but they have not been evaluated to support immunisation in children with anxiety and behavioural challenges. This study assessed the feasibility and acceptability of VR for immunisation in children with needle phobia, including children with and without developmental disabilities.</p><p><strong>Methods: </strong>A mixed method pilot study was conducted at the Royal Children's Hospital, Melbourne. Children with needle phobia aged 4-14 years scheduled for immunisation with distraction and conscious sedation were eligible. VR was offered to children with needle anxiety and/or developmental disabilities before and during immunisation in addition to standard care. Children and caregivers completed electronic surveys pre- and post-immunisation, followed by qualitative interviews post-immunisation. Clinicians completed post-immunisation surveys. Primary outcomes were feasibility and acceptability of VR according to children, caregivers and clinicians.</p><p><strong>Results: </strong>Between May and December 2022, we screened 54 children and included 30; 15 with and 15 without developmental disability. Preparation to use VR took less than five minutes for most children (24/30; 80 %). Twenty nine (96 %) used VR immediately before immunisation, and 17 (57 %) continued using it during immunisation (7 with developmental disability, 10 without). Twenty seven (90 %) children were immunised successfully, with a small reduction in required sedation. Of those who used VR during immunisation, 16/17 (94 %) reported a more positive overall experience. Of those who only used VR before immunisation, 3/13 (23 %) still reported benefit. VR was therefore described as beneficial for 19/30 (63 %) participants (9 with developmental disability, 10 without). Caregivers reported willingness to use VR in future immunisation encounters for 23/30 (77 %) children (11 with developmental disability, 12 without).</p><p><strong>Discussion: </strong>This pilot study suggests VR was feasible and acceptable for many children with needle phobia, both with and without developmental disability. These findings will inform a randomised controlled trial to assess effectiveness.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating influenza vaccine effectiveness among older adults using an integrated administrative database and the implications of potential bias: A population-based cohort study in Japan.","authors":"Ayu Kasamatsu, Yuichiro Yahata, Wakaba Fukushima, Hirofumi Sakamoto, Kaori Tanaka, Miwa Takigawa, Kaori Izu, Yuko Nishino, Motoi Suzuki, Hajime Kamiya","doi":"10.1016/j.vaccine.2024.126488","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126488","url":null,"abstract":"<p><strong>Background: </strong>Japan lacks an established framework for routine seasonal influenza vaccine effectiveness (SIVE) assessment at the national and municipal levels. This study aimed to estimate SIVE among older adults using an innovative population-based administrative database linking medical fee claims data with vaccination records, while also exploring its potential bias.</p><p><strong>Methods: </strong>In this retrospective population-based cohort study, we assessed SIVE against medically attended influenza during the 2017/18 season among older adults aged ≥65 years in a Japanese city. A Cox proportional hazards model was used to estimate hazard rate ratios, treating vaccination status as time-dependent. To explore potential biases, multivariate logistic regression analysis was used to investigate the association between vaccination status and acute respiratory infection (ARI) diagnosis and trauma/injury during the non-influenza season.</p><p><strong>Results: </strong>This study included 82 % (n = 110,892) of the city's older adult population, with 39.7 % vaccination coverage. The estimated SIVE was 2.9 % (95 % confidence interval: -6.2-11.2), showing no statistical significance. Similarly, subgroup analyses by age and comorbidities revealed no significant protective effect of SIVE. In the non-season analysis, adjusted odds ratios of vaccination were significantly higher for ARI [1.3 (1.3-1.4)] and trauma/injury [1.2 (1.1-1.2)]. However, no significance was observed for hospitalizations with these diagnoses, which include severe conditions less associated with healthcare-seeking behaviors [0.9 (0.8-1.1) and 0.8 (0.6-1.0), respectively].</p><p><strong>Conclusions: </strong>No significant SIVE was observed during the 2017/18 season. Our real-world observational study, based on medical fee claims data, indicates a potential underestimation of SIVE owing to bias related to healthcare-seeking behaviors.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RTS, S malaria vaccination among children aged 24-59 months in the Sunyani Municipality, Ghana; 2023.","authors":"Mansulu Mohammed Zacharia, Sorengmen Amos Ziema, Williams Azumah Abanga, Richard Adinkrah Kyeremeh, Christopher Sunkwa Tamal, Michael Rockson Adjei, Chrysantus Kubio","doi":"10.1016/j.vaccine.2024.126490","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126490","url":null,"abstract":"<p><strong>Background: </strong>Following the successful pilot of RTS,S malaria vaccine, it has been recommended by the WHO for prevention of Plasmodium falciparum malaria in children living in endemic areas. Despite the proven benefits of the malaria vaccine, uptake especially of the fourth dose, remains relatively low. We assessed complete uptake of RTS,S malaria vaccine among children 24-59 months and associated factors in the Sunyani Municipality of Ghana.</p><p><strong>Methods: </strong>A cross-sectional study was conducted among 361 caregivers of children aged 24-59 months in the Sunyani Municipality, who had received at least one dose of RTS,S malaria vaccine. Structured questionnaires were administered to caregivers and relevant vaccination information was extracted from the maternal and child health record books. Binary logistic regression analysis was used to determine factors associated with complete uptake of the vaccine at 95 % confidence interval (CI).</p><p><strong>Results: </strong>Approximately 45 % (164/361) of the children had completed the RTS,S malaria vaccination schedule. Children aged 48-59 months (AOR:0.26, 95 %CI:0.09-0.76), those with caregivers who believed that children were being used for experiment (AOR:0.29, 95 %CI:0.16-0.54) or doubted the safety of the vaccine (AOR:0.27, 95 %CI:0.14-0.52) were less likely to complete the four doses. On the other hand, children of caregivers who reported vaccine shortages and travelled long distances to access immunization services (AOR:3.15, 95 %CI:1.17-8.47), and those with adequate knowledge on the malaria vaccine (AOR:1.89, 95 %CI:1.08-3.29) were more likely to complete the vaccination schedule.</p><p><strong>Conclusion: </strong>Less than half of the children who started RTS,S malaria vaccination completed the full schedule. Age of child, caregiver knowledge and perception of the malaria vaccine, and access to immunization service were associated with complete uptake of the RTS,S malaria vaccine. Strengthening caregiver education and access to immunization services could improve uptake of the subsequent doses and coverage of the fourth dose.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice.","authors":"Zalma V Sanchez-Martinez, Sergio P Alpuche-Lazcano, Matthew Stuible, Bassel Akache, Tyler M Renner, Lise Deschatelets, Renu Dudani, Blair A Harrison, Michael J McCluskie, Sabahudin Hrapovic, Julie Blouin, Xinyu Wang, Matthew Schuller, Kai Cui, Jae-Young Cho, Yves Durocher","doi":"10.1016/j.vaccine.2024.126463","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126463","url":null,"abstract":"<p><p>A vaccine effective against both SARS-CoV-2 and influenza A (IAV) viruses could represent a cost-effective strategy to reduce their combined public health burden as well as potential complications arising from co-infection. Based on previous findings that full-length SARS-CoV-2 spike (S) expression can induce high-level, enveloped VLP (eVLP) production in CHO cells, we tested whether IAV H1N1 hemagglutinin (H1) and neuraminidase (N1) could also be displayed on these particles. We found that co-incorporation of the IAV surface antigens in spike VLPs (S-VLPs) was highly efficient: upon transient co-expression of S + H1 or S + H1 + N1 in CHO cells, the resulting VLPs contained similar amounts of the SARS-CoV-2 S and IAV antigens. The self-assembled bivalent (S/H1) and trivalent (S/H1/N1) VLPs released into the culture media were purified by single-step chromatography using a S-VLP affinity resin. Western blot analysis and immuno‑gold labeling transmission electron microscopy (TEM) of purified VLPs confirmed the coexistence of S, H1 and N1 antigens in the same particles. Finally, we demonstrated that two doses of adjuvanted bivalent and trivalent VLPs elicit specific functional antibodies and cellular immunity in a mouse model, suggesting potential for combined SARS-CoV-2/IAV vaccine development.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On-time childhood vaccination before and during the COVID-19 pandemic in seven communities: Findings from the New Vaccine Surveillance Network.","authors":"Annika M Hofstetter, Eileen J Klein, Bonnie Strelitz, Rangaraj Selvarangan, Jennifer E Schuster, Julie A Boom, Leila C Sahni, Natasha B Halasa, Laura S Stewart, Mary Allen Staat, Chelsea Rohlfs, Peter G Szilagyi, Geoffrey A Weinberg, John V Williams, Marian G Michaels, Heidi Moline, Sara A Mirza, Christopher J Harrison, Janet A Englund","doi":"10.1016/j.vaccine.2024.126455","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126455","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic raised unprecedented challenges to vaccinating children. This multi-center study aimed to compare on-time vaccination of children before and during the COVID-19 pandemic and identify key factors associated with on-time vaccination.</p><p><strong>Methods: </strong>This study was conducted among children aged 0-6 years enrolled in the New Vaccine Surveillance Network at seven geographically diverse U.S. academic medical centers. Children with acute respiratory illness or acute gastroenteritis were enrolled from emergency department and inpatient settings; healthy control subjects were enrolled from primary care practices. Vaccination data were collected and verified from patient medical records, immunization information systems, and/or provider documentation. On-time vaccination according to Advisory Committee on Immunization Practices recommendations was compared between pre-pandemic (December 2018-February 2020) and pandemic (March 2020-August 2021) periods using bivariate and multivariable analyses, adjusting for key demographic, clinical, and study characteristics.</p><p><strong>Results: </strong>A total of 24,713 children were included in the analytic sample (non-Hispanic 73.4 %; White 51.0 %; publicly insured 69.0 %). On-time vaccination declined between the pre-pandemic (67.3 %) and pandemic (65.4 %) periods (Adjusted Odds Ratio 0.89, 95 % CI 0.84-0.95). The largest declines were observed among children who were < 12 months, male, Black, publicly insured, or whose mothers had a high school-equivalent education or less. The pandemic impact also varied by vaccine type and study site.</p><p><strong>Conclusions: </strong>This multi-center study revealed a relatively modest overall reduction in on-time vaccination, which may reflect multilevel efforts to address pandemic-associated challenges. However, some patient subgroups and sites experienced greater reductions in on-time vaccination, highlighting the importance of tailoring interventions to increase equitable vaccine delivery, access, and acceptance across populations and communities.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccinations in children of non-European origin: The Vax4globe survey.","authors":"Viviana Moschese, Simona Graziani, Antonietta Spadea, Maurizia D'Amore, Raffaella Mosco, Sara Ciampini, Nicola Di Giorgio, Susanna Arcano, Simona Ceccarelli, Marco Chianca, Simona Piccinini, Antonella Polito, Marta Porcari, Pamela Puliafito, Romina Silenzi, Elisabetta Del Duca, Claudio Pignata, Michele Miraglia Del Giudice","doi":"10.1016/j.vaccine.2024.126466","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126466","url":null,"abstract":"<p><strong>Background: </strong>An equitable immunization coverage to \"leave no one behind\" is one of the World Health Organization Sustainable Development Goals. However, disparities in vaccination coverage exist. The present study aims to investigate vaccine attitude of non-European parents living in Italy and those factors affecting vaccine uptake and equity.</p><p><strong>Methods: </strong>A cross sectional survey, named Vax4globe, on knowledge and immunization compliance in childhood and pregnancy of non-European (non-EU) parents was carried out among general pediatrician and Vaccine Centers located in Lazio Region, between February and July 2023. Logistic regression models were used in univariate and multivariate analyses to examine the socio-demographic parameters mainly associated with the vaccination status.</p><p><strong>Results: </strong>A total of 310 parent/child pair were included in the study. Most children were born in Italy (262/310; 86.5 %), while while 40/310 (13.2 %) migrated from country of origin and 1/310 (0.3 %) was adopted. Mandatory vaccines were perfomed by 270/306 (88 %) children, however flu, papillomavirus and meningococcal group B were vaccines most commonly refused by 208/289 (72 %), 11/36 (31 %) and 9/36 (25 %) parents, respectively. A lower educational degree of parents (p = 0.040) and the migration status of children (p < 0.001) were associated to incomplete or missed immunization. As to maternal immunization 164/310 (53 %) non-EU women decided not to vaccinate and received less information (155/297;52 %) compared to childhood immunization (268/305; 88 %) (p < 0.0001). The educational degree (p = 0.017), the origin from non-EU European countries (p = 0.008) and the age 25-40 years (p = 0.036) and > 40 years (p = 0.007) were associated to lack of immunization during pregnancy. Finally, while 279/310 (90 %) parents were vaccinated against Sars-CoV-2, only 60/199 (30 %) children had been immunized with this vaccine mainly due to the non-mandatory vaccine request at pediatric age and to the doubts about its value according to 39/127 (31 %) and 29/127 (23 %) parents, respectively.</p><p><strong>Conclusion: </strong>Our study highlights the need for targeted strategies to improve vaccine uptake both in childhood and in pregnancy among non-EU individuals living in Italy. Further, to achieve vaccination equity the role of institutions and healthcare personnel is pivotal to overcome vaccine hesitancy.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Influenza B/Yamagata - extinct, eradicated or hiding? [Vaccine 42/26 (2024) 126450]\".","authors":"Chandini R MacIntyre, Zubair Akhtar, Aye Moa","doi":"10.1016/j.vaccine.2024.126486","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126486","url":null,"abstract":"","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudomonas aeruginosa elongation factor-Tu (EF-Tu) is an immunogenic protective protein antigen.","authors":"Dina A Moustafa, Emma Lou, Morgan E Schafer-Kestenman, Margalida Mateu-Borrás, Antonio Doménech-Sanchez, Sebastián Albertí, Joanna B Goldberg","doi":"10.1016/j.vaccine.2024.126476","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126476","url":null,"abstract":"<p><p>Pseudomonas aeruginosa is a Gram-negative, opportunistic pathogen that infects immunocompromised individuals, especially in the hospital setting. This bacterium is an important pathogen in people with weakened immune systems, injuries, and other underlying physiologic dysfunctions. P. aeruginosa is responsible for up to 20 % of all hospital-acquired pneumonias. It is one of the major causes of nosocomial infections and has been noted to be one of the most common bacteria co-infecting patients with COVID-19 or causing super-infections following COVID-19 infections. Despite improvements in antimicrobial therapy and hospital care, P. aeruginosa bacteremia and pneumonia remain fatal in about 30 % of cases. P. aeruginosa is also the leading cause of chronic life-threatening lung infections in cystic fibrosis patients. This bacterium is naturally antibiotic resistant, and infections are notoriously difficult to treat once established, with no vaccine available. We have previously shown that elongation factor-Tu (EF-Tu), a protein best known for its role in protein synthesis, is surface exposed on P. aeruginosa. As this protein is highly expressed, evolutionally conserved, and essential, we hypothesized it would make a good vaccine target. In this study, we found that P. aeruginosa EF-Tu is immunogenic in people, and that mice can develop an immune response following immunization with recombinant P. aeruginosa EF-Tu. Furthermore, immunized mice were protected from subsequent P. aeruginosa pneumonia and transfer of this vaccine antisera to naïve mice resulted in decreased colonization. Altogether these findings support the consideration of EF-Tu as a new vaccine candidate against P. aeruginosa.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging global patterns of COVID-19 vaccine information fatigue in 23 countries in 2023.","authors":"Trenton M White, Jeffrey V Lazarus, Kenneth H Rabin, Scott C Ratzan, Ayman El-Mohandes","doi":"10.1016/j.vaccine.2024.126475","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126475","url":null,"abstract":"<p><p>Vaccine information fatigue, exacerbated by the infodemic, misinformation, and cultural influences, hampers public responsiveness to the uptake of vaccines for COVID-19 and other vaccine-preventable diseases. This cross-sectional study of 23,000 respondents surveyed in 23 countries in October 2023 analyzed trust in information sources, perceptions of the pandemic's conclusion, and confidence in one's ability to discern false information from true and the association of these factors with willingness to pay attention to COVID-19 vaccine information, adjusting for sociodemographic characteristics. Results revealed that satisfaction with health authority communication was positively associated with individuals' willingness to pay attention to COVID-19 vaccine information in all 23 countries. Confidence in one's own capacity to distinguish true information from false was associated with willingness in 20 countries. Belief that the pandemic is over was associated with unwillingness to pay attention to COVID-19 vaccine information in 14 countries. These findings underscore the need for tailored communication strategies that build trust in information sources, combat complacency, and enhance discernment skills to address vaccine and pandemic fatigue, aiming to sustain public engagement with vaccine information and, ultimately, support vaccination efforts.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing COVID-19 booster vaccine acceptance in the United Kingdom, Germany, Austria, and Jordan: The role of protection motivation theory, conspiracy beliefs, social media use and religiosity.","authors":"Judith Eberhardt, Walid Al-Qerem, Jonathan Ling","doi":"10.1016/j.vaccine.2024.126474","DOIUrl":"https://doi.org/10.1016/j.vaccine.2024.126474","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus Disease 2019 (COVID-19) booster vaccine uptake has been lower than that of the initial vaccine doses in many countries. Approaches to vaccination vary, with some countries implementing mandatory vaccination and others not. This study aimed to predict COVID-19 booster vaccination intention using Protection Motivation Theory (PMT), coronavirus conspiracy beliefs, social media use, and sociodemographic factors, comparing the United Kingdom (UK), Jordan, Germany, and Austria.</p><p><strong>Methods: </strong>A cross-sectional online survey was conducted in the UK, Germany, Austria, and Jordan. Convenience sampling was used to recruit 287 fully vaccinated participants. The survey included items measuring PMT constructs, conspiracy beliefs, social media use, and sociodemographic variables. Data were analysed using bivariate analysis and binary logistic regression.</p><p><strong>Results: </strong>Participants with high booster dose intention showed lower religiosity, conspiracy beliefs, perceived rewards of not getting vaccinated, and perceived costs of getting vaccinated. They had higher Twitter use, perceived susceptibility, severity of COVID-19, self-efficacy, and vaccine efficacy. Four PMT constructs (severity, self-efficacy, maladaptive response rewards, and response efficacy) significantly predicted booster dose intention.</p><p><strong>Conclusions: </strong>While PMT constructs predict booster vaccination intention, additional factors such as conspiracy beliefs, social media use, and religiosity need to be taken into account in public health campaigns to increase COVID-19 booster dose uptake.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}